Last reviewed · How we verify

AR101 powder provided in capsules — Competitive Intelligence Brief

AR101 powder provided in capsules (AR101 powder provided in capsules) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oral immunotherapy. Area: Allergy.

phase 2 oral immunotherapy Allergy Biologic Live · refreshed every 30 min

Target snapshot

AR101 powder provided in capsules (AR101 powder provided in capsules) — Aimmune Therapeutics, Inc.. AR101 is an oral immunotherapy for peanut allergy.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AR101 powder provided in capsules TARGET AR101 powder provided in capsules Aimmune Therapeutics, Inc. phase 2 oral immunotherapy
Multi-Allergen Oral Immunotherapy Multi-Allergen Oral Immunotherapy National Institute of Allergy and Infectious Diseases (NIAID) phase 3 Oral immunotherapy (OIT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oral immunotherapy class)

  1. Aimmune Therapeutics, Inc. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AR101 powder provided in capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/ar101-powder-provided-in-capsules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: